Clinical Trial Update: ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis [Phase 2]

View source ↗

Summary

Phase 2 trial comparing ATI-501 oral suspension to placebo in subjects with alopecia areata, alopecia universalis, or alopecia totalis has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia
• Alopecia Areata
• Alopecia Totalis
• Alopecia Universalis

Drugs mentioned

• ATI-501 (ATI-501)

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Alopecia | Phase 2 | Status: COMPLETED | Results posted: 2020-09-16